tbuckley/cabot-search huggingface dataset:
Rapid reperitonealization and wound healing in a preclinical model of abdominal trauma repair with a composite mesh
Authors: L. Shapiro, J.-L. Holste, T. Muench, G. diZerega
Journal: International Journal of Surgery (2015)

Peritoneal tissue healing is characterized by the simultaneous repopulation of mesothelial cells and the formation of neoperitoneum. Despite the common use of mesh products for abdominal wall repair, there are few investigations of how these materials may impact the peritoneal healing process. Here, we utilized an animal model of abdominal trauma to specifically investigate the peritoneal healing process in conjunction with a composite (poliglecaprone 25-coated polypropylene) mesh.Abdominal wall injury was simulated in New Zealand White rabbits and peritoneal tissue was covered with composite mesh and fixed with peripheral sutures. Animals were sacrificed at regular intervals (up to 28 days) for macroscopic and microscopic evaluation.Mesothelial cells were consistently identified on the surface of the central areas of the implanted mesh as early as 3-5 days after implantation. From day 7 onward, the entire mesh surface was covered by neoperitoneum which matured over the remaining study intervals. Fibroblast ingrowth of the mesh was apparent by day 5 and increased over time, concurrent with fragmentation of the film on the composite mesh.These results suggest that composite mesh products used for abdominal wall repair do not significantly delay mesothelial repopulation. Study results also support the hypothesis that mesothelial cells involved in healing are derived, at least in part in this model, from free-floating precursor cells located within the peritoneal cavity.
Relationship Between Chromosome Ploidy and Radiosensitivity in Selected Tumor Sublines of Common Origin&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Láiszló Révész, Ulla Norman
Journal: JNCI Journal of the National Cancer Institute (1960)

A predominantly hypertetraploid subline, ELT/stock was derived from a predominantly hyperdiploid Ehrlich ascites tumor, ELD, after homotransplantation of sublethally X-irradiated cells. The ploidy shift was probably the result of immunoselection based on the differential resistance of the polyploid cells against the homograft reaction. Two additional sublines, a pure hypertetraploid, ELT/clone, and a predominantly hyperdiploid population, ELTD, were subsequently selected from ELT/stock. The former was obtained by isolating a hypertetraploid clone (s), and the latter by carrying ELT/stock in serial passage in the absence of immunoselection, in which case hyperdiploid cells regain dominance. The ELTD subline was cytologically indistinguishable from the main ELD line. After irradiation in vitro with different X-ray doses, all sublines were grown intraperitoneally within Millipore diffusion chambers with an average pore size of 0.45 µ, thus isolated from direct contact with host cells. The size of cell population was determined quantitatively at various intervals after inoculation. The growth behavior of all untreated sublines was closely similar. There was a difference in their radiosensitivity, however. After the same dose of X rays, the hypertetraploid sublines started to grow earlier and/or reached a larger population size than the hyperdiploid lines.
The Tragedy of Childbed Fever
Authors: John S G Blair
Journal: BMJ (2001)

Irvine Loudon 

Oxford University Press, £40, pp 250

ISBN 0 19 820499 X

Rating: ![Graphic][1] ![Graphic][2] ![Graphic][3] 

This is an extended monograph about a once terrifying infection, whose reality is now recalled only by those who lived in the pre-antibiotic era. Its whole history is covered—early beliefs about the nature of the disease, the importance of midwives, the epidemics within the death houses that lying-in hospitals became, the succession of …

 [1]: /embed/inline-graphic-1.gif
 [2]: /embed/inline-graphic-2.gif
 [3]: /embed/inline-graphic-3.gif
Homocysteine, Folate, Vitamin B&lt;SUB&gt;6&lt;/SUB&gt;, and Cardiovascular Disease
Authors: Kilmer S. McCully
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Laboratory handling of Helicobacter pylori critically influences the results of in-vitro metronidazole resistance determination
Authors: T.H. Henriksen, F. Lerang, A. Lia, R. Schøyen, T. Thoresen, T. Berge, E. Ragnhildstveit, Y. Tveten, A. Berstad
Journal: Clinical Microbiology and Infection (2004)
Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients
Authors: Hironobu Minami, Kenji Kawada, Yasutsuna Sasaki, Tadahiko Igarashi, Toshiaki Saeki, Makoto Tahara, Kuniaki Itoh, Hirofumi Fujii, Kaori Matsuzawa
Journal: Cancer Research (2005)

6173  Purpose α1-acid glycoprotein (AGP) binds docetaxel in plasma and is a significant determinant of clearance and activity of this drug. This emphasizes the importance of investigating the pharmacology of unbound rather than total docetaxel in plasma. The pharmacokinetics and pharmacodynamics of unbound docetaxel were investigated in cancer patients treated with the drug. Patients and methods: Docetaxel was infused over one hour every 3 weeks in 69 patients with various cancers including 30 patients with breast cancer. In 47 patients, treatment was at the dose approved in Japan, 60 mg/m2, but the other patients received reduced doses at the discretion of their physicians. The concentration of docetaxel was measured at the end of infusion in ultrafiltrate of plasma and the unbound fraction (fu) was calculated by dividing unbound concentrations by total concentrations. The area under the concentration-time curve (AUC) of total docetaxel was calculated using a 3-compartment model. The AUC of unbound docetaxel was calculated by multiplying fu and AUC of total docetaxel. Toxicities were monitored at least weekly. Patient characteristics and pharmacokinetic parameters including the peak concentration at the end of infusion (Cmax) and AUC of total and unbound drug were compared between patients who did or did not experience grade 4 neutropenia. Results: The median of fu was 4.0% ranging widely from 1.2 to 22.6% (5-95% percentile; 1.4-10.5%). Grade 4 neutropenia was observed in 24 patients. The AUC was 2.68 (range, 1.35 - 12.2) and 0.113 (0.033 - 1.12) μg x hour/mL for total and unbound docetaxel, respectively, and Cmax was 1588 (576 - 3535) and 70.9 (16.9 - 349.8) ng/mL, respectively. AGP levels were negatively correlated with the clearance of total docetaxel (r=-0.28, p=0.026) and positively correlated with neutrophil counts before treatment (r=0.46, p=0.0002), but not with the clearance of unbound docetaxel. When pharmacokinetic parameters were compared between patients with or without grade 4 neutropenia, those experiencing neutropenia had significantly greater Cmax (92.3 vs. 63.3 ng/mL, p=0.01) and AUC (0.137 vs. 0.104 μg x hour/mL, p=0.05) of unbound docetaxel, but Cmax and AUC of total drug were not different. Other factors associated with grade 4 neutropenia in univariate analysis were female sex, breast cancer, AGP, and pretreatment neutrophil counts. In a multi-variate logistic regression analysis, the unbound Cmax and AGP were found to be determinants of grade 4 neutropenia, and higher Cmax and lower AGP levels were associated with greater risk of grade 4 neutropenia. Conclusion: Pharmacokinetics of unbound rather than total drug is a better predictor of pharmacodynamics for docetaxel, and AGP is an important factor influencing pharmacokinetics as well as pharmacodynamics of this drug.
A Combination of Retinoic Acid and Proteasome Inhibitors for the Treatment of Leukemias Is Potentially Dangerous
Authors: Cezary Wójcik, Izabella Młynarczuk, Graz˙yna Hoser, Jerzy Kawiak, Tomasz Stokłosa, Jakub Gołab, Sherwin Wilk
Journal: Blood (1999)
Abstract 3761: Nanoliposomal c-MYC-siRNA inhibits <i>in vivo</i> tumor growth of cisplatin-resistant ovarian cancer
Authors: Jeyshka M. Reyes-González, Guillermo N. Armaiz, Lingegowda S. Mangala, Fatma Valiyeva, Sunila Pradeep, Anil K. Sood, Pablo E. Vivas-Mejía
Journal: Cancer Research (2014)

Abstract Ovarian cancer is the deadliest of gynecological cancers in the United States. With fewer than 15% of cases diagnosed early, ovarian cancer continues to be characterized by late-stage presentation. Treatment for ovarian cancer usually involves surgical cytoreduction followed by platinum-based chemotherapy. Unfortunately, despite initial respond, more than 70% of ovarian cancer patients develop cisplatin resistance, relapse and therapeutic failure. Therefore, there is a need of novel therapies focused on targets within cancer cell survival pathways for advanced stage drug resistant ovarian cancer. Evidence indicates that activation of the oncogenic transcription factor c-MYC is involved in drug resistance. Our previous findings indicate that cisplatin-resistant ovarian cancer cells express higher c-MYC protein levels when compared to their sensitive counterparts. Importantly, targeting c-MYC with small interfering RNA (siRNA) in the cisplatin-resistant ovarian cancer cell line, A2780CP20, induced a significant cell growth arrest and inhibition of cell proliferation. Apoptosis and arrest of cell cycle progression were also observed after siRNA-based silencing of c-MYC. These results were confirmed by Western blot analysis. Furthermore, in vivo delivery of c-MYC-siRNA in a murine xenograft model of cisplatin-resistant ovarian cancer was achieved by using DOPC/PEG-2000-based nanoliposomes. A single weekly injection of nanoliposomal c-MYC-siRNA, during a four week period, decreased tumor weight and number of tumor nodules compared with a liposomal-negative control siRNA. These data propose c-MYC as a potential therapeutic target for cisplatin-resistant ovarian cancer. Citation Format: Jeyshka M. Reyes-González, Guillermo N. Armaiz, Lingegowda S. Mangala, Fatma Valiyeva, Sunila Pradeep, Anil K. Sood, Pablo E. Vivas-Mejía. Nanoliposomal c-MYC-siRNA inhibits in vivo tumor growth of cisplatin-resistant ovarian cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3761. doi:10.1158/1538-7445.AM2014-3761
Spirochetemia due to Treponema pallidum using polymerase-chain-reaction assays in patients with early syphilis: prevalence, associated factors and treatment response
Authors: B.-R. Wu, M.-S. Tsai, C.-J. Yang, H.-Y. Sun, W.-C. Liu, S.-P. Yang, P.-Y. Wu, Y.-C. Su, S.-Y. Chang, C.-C. Hung
Journal: Clinical Microbiology and Infection (2013)
Abstract P198: Clinic versus Out-of-Clinic Daytime Blood Pressure Among Older Adults: Data From the Jackson Heart Study
Authors: Rikki M Tanner, Daichi Shimbo, Samantha Seals, Gbenga Ogedegbe, Paul Muntner
Journal: Circulation (2015)

In the US, antihypertensive medication treatment decisions are primarily based on blood pressure (BP) measurements obtained in the clinic setting. The optimal systolic BP (SBP) goal for adults ≥60 years is controversial and a large difference between clinic and out-of-clinic daytime BP, a white-coat effect, may be present in older individuals. We estimated the white-coat effect and calculated the percentage of untreated and treated adults &lt;60 and ≥60 years with elevated clinic BP (defined as SBP/diastolic BP [DBP] ≥140/90 mmHg), but non-elevated out-of-clinic daytime BP (“daytime BP”, defined as SBP/DBP &lt;135/85 mmHg) among 257 African-American participants in the Jackson Heart Study with at least 10 daytime ambulatory BP measurements. For the overall population, the white-coat effect for SBP was 12.2 mmHg (95% confidence interval [CI]: 9.2-15.1) in older adults and 8.4 mmHg (95% CI: 5.7-11.1) in younger adults (p=0.06). After multivariable (MV) adjustment, this difference was 1.3 mmHg. Among those without diabetes or chronic kidney disease (CKD), the white coat effect for SBP was 15.2 mmHg (95% CI: 10.1-20.2) and 8.6 mmHg (95% CI: 5.0-12.3) for older and younger adults, respectively (p=0.04). After MV adjustment, this difference was 5.9 mmHg. Also, SBP ≥150 mmHg versus &lt;150 mm Hg was associated with a larger white-coat effect in the overall population after MV adjustment. Among those without CKD or diabetes, older age and SBP ≥150 mmHg were associated with a larger white-coat effect after MV adjustment. Among younger and older participants with elevated clinic BP, the prevalence of non-elevated daytime BP was 34% (95% CI: 26%-44%) and 32% (95% CI: 24%-40%), respectively (p=0.64), in the overall population and 35% (95% CI: 24%-48%) and 43% (95% CI: 31%-56%), respectively, for those without CKD or diabetes (p=0.37). In conclusion, a large white-coat effect was present among older adults. These data suggest a role for ambulatory blood pressure monitoring in preventing potential over-treatment for hypertension among older adults.
Serum and pleural fluid cytokines in pleural tuberculosis with and without lung parenchyma involvement
Authors: Marcia Seiscento, Francisco Vargas, Roberta Sales, Lisete Teixeira, Juliana Puka, Milena Acencio, Leila Antonangelo
Journal: European Respiratory Journal (2011)

Pleural tuberculosis (PT) is frequent form of extrapulmonary disease. In the pleural cavity, activated T lymphocytes produce cytokines in response to the mycobacteria and its antigens. Lung parenchyma can be concomitantly involved in up to 40% of cases.   Objective:  To compare serum (S) and pleural fluid (PF) levels of inflammatory mediators in patients with PT in order to verify if lung-associated involvement influences the magnitude of the inflammatory response.   Methods:  A prospective study of 39 patients with pleural (20) or pleuropulmonary (19) tuberculosis was conducted. IL-8, VEGF, TNF-α, and TGF-β1 were quantified by ELISA.   Results  The proinflammatory cytokines TNF-α and IL-8 were higher in PF than in S of patients with the pleural form, while only IL-8 was higher in the pleuropulmonary form. Only PF TNF-α was capable to discriminate both forms of TB disease.   Conclusion:  Although TNF-α levels had been higher in the PF of patients with PT and lung involvement, we suggest its dosage in association with computed tomography in order to identify these patients, since they represent potential source of infection and disease spread.
Abstract 3593: Examining the role of tumor cell secreted factors in intravasation and enhancing paracrine loop invasion
Authors: Ramon M. Cabrera, Zhen N. Zhou, Minna Roh-Johnson, John Condeelis, Dianne Cox, Jeffrey E. Segall
Journal: Cancer Research (2014)

Abstract The interaction of breast cancer cells with other cells in the tumor microenvironment plays an important role in metastasis. Invasion and intravasation, two critical steps in the metastatic process, are thought to be influenced by these interactions in addition to their intrinsic invasive properties. Macrophages are of particular interest when it comes to studying tumor cell invasiveness. Previous studies have shown that there is paracrine loop signaling between breast cancer cells and macrophages in which colony stimulating factor 1 (CSF-1) produced by tumor cells stimulates epidermal growth factor (EGF) production by macrophages. This EGF, in turn, stimulates invasion of the tumor cells. In addition to the classically described paracrine loop, it has been seen that tumor cell expression of ErbB3, a member of the EGFR family of receptor tyrosine kinases, may play a role in facilitating tumor cell intravasation. Overexpression of ErbB3 in breast cancer patients correlates with decreased survival. We show that using a blocking antibody against ErbB3 results in a significant decrease in macrophage-induced transendothelial migration of breast cancer cells. Tumor cell secretion of Neuregulin 1 (NRG1), a ligand of the ErbB3 receptor, may also play a role in the tumor cell- macrophage paracrine interaction. We show that stimulation of macrophages with NRG1 upregulates mRNA expression of JAG1, a ligand of the Notch receptor. Activation of the Notch receptor pathway has been shown to be involved in the process of tumor cell invasion. Overall, our studies look to examine this interaction between tumor cells and macrophages and these observations indicate that ErbB3, NRG1, and JAG1 could serve as novel targets in metastasis and the tumor microenvironment. Citation Format: Ramon M. Cabrera, Zhen N. Zhou, Minna Roh-Johnson, John Condeelis, Dianne Cox, Jeffrey E. Segall. Examining the role of tumor cell secreted factors in intravasation and enhancing paracrine loop invasion. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3593. doi:10.1158/1538-7445.AM2014-3593
SLC7A7, encoding a putative permease-related protein, is mutated in patients with lysinuric protein intolerance
Authors: Giuseppe Borsani, Maria Teresa Bassi, Maria Pia Sperandeo, Alessandro De Grandi, Anna Buoninconti, Mirko Riboni, Marta Manzoni, Barbara Incerti, Antonio Pepe, Generoso Andria, Andrea Ballabio, Gianfranco Sebastio
Journal: Nature Genetics (1999)
X-RAYS: THE EFFECT OF THE ANGLE OF INCIDENCE.
Authors: E. H. MOLESWORTH
Journal: British Journal of Dermatology (1935)

Journal Article X‐RAYS: THE EFFECT OF THE ANGLE OF INCIDENCE: A REPLY TO THE EDITOR'S COMMENT Get access E. H. MOLESWORTH, M.D. E. H. MOLESWORTH, M.D. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology and Syphilis, Volume 47, Issue 10, 1 October 1935, Pages 405–406, https://doi.org/10.1111/j.1365-2133.1935.tb09818.x Published: 01 October 1935
Abstract 11844: Optimal Therapeutic Management Improves Long-Term Survival in ST-Elevation Myocardial Patients With Altered Glomerular Filtration Rate. A Propensity Score Comparison
Authors: Nathan Mewton, Fabien Subtil, Oualid Zouaghi, Julie Mahé, Brigitte De Breyne, Eric Bonnefoy-Cudraz
Journal: Circulation (2014)

Introduction: Patients with chronic kidney disease have more comorbidities and will receive fewer evidence-based therapies. Hypothesis: In a prospective ST-elevated myocardial infarction (STEMI) patient cohort we assessed the effect of an optimal therapeutic management (OTM) according to GFR categories on long-term all-cause mortality. Methods: 1,199 patients admitted for acute STEMI were enrolled between 2007 and 2011 at our university hospital. We classified patients into 4 categories according to estimated GFR, 90 mL/min/1.73 m2 with the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) equation. Optimal therapeutic management was defined as a combination of reperfusion within 12 hours of symptom onset, primary percutaneous coronary intervention (PCI), double anti-platelet regimen, angiotensin converting enzyme inhibitors, statins, beta blockers, and anti-aldosterone treatment (if left ventricle ejection fraction <40%) upon discharge. The effect of OTM on survival according to GFR categories ...
THE USES OF ELEGANCE
Authors: D W ATCHLEY
Journal: Annals of Internal Medicine (1960)

An Address1 April 1960THE USES OF ELEGANCEDANA W. ATCHLEY, M.D., F.A.C.P.DANA W. ATCHLEY, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-52-4-881 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptElegance is an attribute which stimulates a variety of responses. Its wide spectrum of meaning renders precise definition somewhat difficult, for its usage has developed far beyond its Latin root, to select. This discussion of elegance assumes that it is a quality which evokes unexpected and attentive admiration and is the result of discriminative selection, a definition embracing the wide range between a tastefully ornate costume, an exceptionally neat scientific experiment and a brilliantly original concept. An exchange student from Greece, writing inThe American Scientiston "Simplicity and Elegance in Theoretical Physics," defined elegance as "the principle that postulates... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, N. Y.*Address delivered at the Gold-Headed Cane Ceremony, University of California School of Medicine, San Francisco, on June 10, 1959.†Emeritus Professor of Clinical Medicine, College of Physicians and Surgeons, Columbia University, and Consultant in Medicine, Presbyterian Hospital.Requests for reprints should be addressed to the Editorial Office, Department of Medicine, University of California Medical Center, San Francisco 22, California. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 April 1960Volume 52, Issue 4Page: 881-889KeywordsHospital medicineScientistsSurgeons ePublished: 1 December 2008 Issue Published: 1 April 1960 PDF downloadLoading ...